Advertisement

Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa


Advertisement
Get Permission


Related Articles

How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life

Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...

Advertisement

Advertisement




Advertisement